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The process of high-throughput drug discovery typically involves
screening protein targets against existing compounds to identify
those which bind with high speciﬁcity and afﬁnity1,2. Unfortu-
nately, this strategy can result in unexpected or undetected off-
target effects that lead to high attrition rates in the later stages of
drug development. More appealing would be the unbiased
identiﬁcation of proteins and associated complexes to which a
drug or drug candidate binds since it would enable direct
evaluation and provide valuable insights into target cellular
functions. One of the most widely applied methodologies to
characterize proteins that bind speciﬁcally to candidate com-
pounds is based on afﬁnity chromatography combined with mass
spectrometry-based quantitative proteomics. Small molecule-
based afﬁnity chromatography was ﬁrst used for the puriﬁcation
of protein targets as early as the 1960s3. Since then, in combi-
nation with mass spectrometry-based quantitative proteomics,
it has become one of the most widely applied techniques to
characterize proteins that bind speciﬁcally to drug candidates4.
In afﬁnity chromatography, a small bioactive molecule is
immobilized onto a solid phase support and then incubated with
a protein extract. After incubation, the afﬁnity resin is washed
extensively with an aqueous buffer to elute any non-binding
proteins from the resin. Bound proteins are then eluted from the
afﬁnity matrix under denaturing conditions or by incubation
with the free ligand and resolved by SDS-PAGE5. Finally, the
proteins are identiﬁed by mass spectrometric analysis. Once a
putative target protein has been identiﬁed, several follow-up
experiments can be carried out to conﬁrm the interaction with
puriﬁed protein. Direct binding can be analyzed by ﬂuorescence
anisotropy, isothermal titration calorimetry, or surface plasmon
resonance. If the target is an enzyme, the compound or its
analogs can be tested as potential inhibitors. A number of
protein targets of biologically important natural products and
small molecules have been discovered using this approach.2. Synthesis of afﬁnity matrix
2.1. Solid phase support
The ﬁrst step is to immobilize the small bioactive molecule onto a
solid phase resin. The latter is typically an agarose or sepharose-
based polymer that is functionalized with reactive functional
groups such as amines, thiols, or carboxylic acids6. Drawbacks of
afﬁnity chromatography with such conventional matrices include
non-speciﬁc binding of proteins, chemical instability and incom-
patibility with some chemical modiﬁcation procedures. To solve
these problems, Handa and coworkers7–9 developed a matrix
composed of a styrene and glycidyl methacrylate copolymer core
and a glycidyl methacrylate polymer surface in the form of a
non-porous bead (called SG beads). The extremely small size of
the beads (0.2 mm on average) provides a large surface area to
increase the capture efﬁciency of target proteins and their non-
porous nature allows easy removal of non-speciﬁcally bound
proteins. This matrix also has good chemical and physical
stability, high capacity for ligand attachment and high puriﬁ-
cation efﬁciency. Other matrices like poly(methacrylate)10–12,
poly(acrylamide) polymers13 and monolithic materials14–18 have
also been used to produce afﬁnity resins with reduced non-
speciﬁc protein absorption and increased chemical stability.Using a conventional support, it is always difﬁcult to perform
multiple parallel experiments due to the need to remove back-
ground proteins and separate resin by ﬁltration or centrifugation.
One way to overcome this is to utilize a magnetic support. These
are now being widely used for bioseparations because they can be
easily separated using a permanent magnet19–21. This improves the
efﬁciency of the binding, washing and elution steps in the afﬁnity
enrichment process. Due to their low toxicity and stable magnetic
properties, magnetite (Fe3O4) nanoparticles have been investigated
for potential application in bioseparation, biosensing, drug deliv-
ery, magnetic ﬂuid hyperthermia, and magnetic resonance imaging
contrast enhancement22. Such nanobeads are also useful as a
matrix material because they offer a large surface area for binding
and are easy to resuspend and recover.
For the efﬁcient capture of drug targets which are often
expressed in very low abundance, carriers of nanometer size that
are highly dispersible are desirable. It is also important that
carriers retain their dispersibility and polymer coating in organic
solvents since most drugs are water insoluble and require dissol-
ving in organic solvents when synthesizing afﬁnity beads. Further-
more, carrier surfaces must exhibit low non-speciﬁc binding of
proteins because a large non-speciﬁc background signal can
interfere with the identiﬁcation of low-abundance targets.2.2. Cell-permeable support
In a typical afﬁnity chromatographic puriﬁcation, a cell lysate or
tissue homogenate is incubated with the afﬁnity matrix under
conditions designed to minimize protein degradation, typically
4 1C in the presence of protease inhibitors. Since the protein is
not in its native physiological state, such studies remain prone to
detecting false positives23 and may also involve loss of some
target proteins during sample preparation. To probe potential
protein targets in living systems, the activity based protein
proﬁling (ABPP) strategy has been successfully introduced for
the study of enzyme families in vivo24. ABPP probes function on
the basis of either a covalent reaction with the target protein or
photoafﬁnity labeling by the incorporation of photoreactive
groups. One important issue to consider is that many important
ligands are either hydrophobic or negatively charged and are
unable to penetrate the cell membrane of living cells23. The use of
cell-penetrating peptides may facilitate drug penetration into
living cells25–27 but their use requires design of a conjugate to
which it may be hard to attach other groups like a ﬂuorescent
tag. Accordingly, the establishment of a general in situ approach
to probe intracellular protein targets is highly desirable.
Hu et al.28 introduced soluble nanopolymers (i.e., dendrimers)
as matrices for the immobilization of bioactive small molecules.
Dendrimers are highly branched nanomolecules with attractive
properties as drug delivery vehicles and imaging contrast agents.
They have excellent solubility, high structural homogeneity,
controlled surface functionalities, cell permeation ability, and
low cytotoxicity29,30. The soluble dendrimer is multifunctionalized
with drug candidates intended to promote speciﬁc interactions
with protein targets, and with ‘‘handle’’ groups that facilitate ﬁnal
isolation through a highly efﬁcient conjugation (Fig. 1). In a
proof-of-concept study, anticancer drug methotrexate (MTX) was
used as a model drug. Two proteins known to interact with MTX,
dihydrofolate reductase (DHFR) and deoxycytidine kinase (dCK),
were identiﬁed by this approach as intracellular drug targets. This
strategy based on multifunctionalized soluble nanopolymers
Figure 1 Schematic representation of the soluble nanopolymer-
based approach to identify drug targets.
Figure 2 (A) Model structures of the polyproline linker (Clea-
vage site of HRVC3 protease is shown in bold italic letters and
conjugate 11 has no cleavage site.) and (B) its application as a
probe to isolate the target proteins, COX1 and GLO132.
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proteins in vitro and in living cells. It has a number of advantages
over existing methods including the presence of multiple sites of
attachment to facilitate the synthesis of intracellular probes and, in
combination with mass spectrometry, the ability to provide
sensitive, fast identiﬁcation of proteins of interest in the most
physiologically relevant environments. More importantly, a lot of
hydrophobic or negatively charged drugs or prodrugs can be
immobilized on dendrimers to improve their bioavailability. If at
the same time they retain their bioactivity, it will broaden the
application of this new strategy to many important biological
systems.
2.3. Spacer arm
The procedure for immobilization of a compound on a solid
support often involves a spacer arm to improve the efﬁciency
of the interaction with target proteins in a cell lysate or tissue
extract. Compounds are typically attached to the support
through a long, hydrophilic linker such as a polyethylene
glycol (PEG) chain31. Biological activity of the linker-functio-
nalized compound is then determined to conﬁrm that it
interacts with the same proteins as the parent molecule.
Besides minimizing non-speciﬁc binding, the hydrophilic
nature of the linker separates the probe compound from the
surface of the resin and gives it greater conformational
ﬂexibility so that it can assume a favorable binding orientation
and allow efﬁcient target protein interaction.
Sato et al.32 designed a rod-like polyproline helix linker
instead of the more commonly used PEG group (Fig. 2). The
chain of nine L-prolines formed a stable left-handed helix of
length 27 A˚ as measured by ﬂuorescence resonance energy
transfer experiments. The rigidity of the polyproline helix
probably prevents its folding to permit better interaction with
target proteins. In comparing the polyproline linker with a
PEG linker of length 32 A˚, Sato et al. found they could purify
o25% of the target protein obtained using the polyproline
linker. Furthermore, they isolated glyoxalase 1 as a new target
of indomethacin, a clinically used nonsteroidal antiinﬂamma-
tory drug that is known to inhibit cyclooxygenases. This
further conﬁrmed the ability of a rod-like linker to increase
the capacity of afﬁnity puriﬁcation and the efﬁciency of
separating low-abundance or low-afﬁnity proteins.3. Challenges for afﬁnity enrichment
3.1. Non-speciﬁc interaction
In characterizing the speciﬁc binding partner(s) of a bioactive
small molecule, a major challenge is to eliminate non-speciﬁcbinding proteins. This is because (1) the abundance of target
proteins is often very low and their afﬁnity and speciﬁcity for the
probe is unknown and (2) many drugs bind to carrier proteins
such as serum albumin or other highly abundant proteins like
tubulin. Various approaches have been evaluated to remove non-
speciﬁc binding proteins. For instance, Handa and co-workers7,9
developed latex beads which considerably reduced non-speciﬁc
interactions between sticky proteins and the solid support. The
inclusion of detergents, salts or denaturing agents is another way
to increase elution of non-speciﬁc proteins. Although more
stringent washing may be used, it increases the risk of losing
weakly binding target proteins. Introduction of a speciﬁc cleavage
linker (as in tandem afﬁnity puriﬁcation33) is another way to
reduce contamination with non-speciﬁc binding proteins. As an
example, Mano et al.34 immobilized small molecules on an agarose
gel through a disulﬁde linker that is cleavable by mild reduction.
This system allowed speciﬁc and non-covalent complex formation
between the small molecule and the target protein whilst reducing
binding of non-speciﬁc proteins to both the linker and gel surface
to a minimum. Using deoxycholate as a model compound, Mano
et al. captured two deoxycholate-binding proteins from mouse
ascites with no accompanying non-speciﬁc binding proteins. More
speciﬁc elution can be achieved by competition with free com-
pounds8,35 but many compounds do not dissolve in aqueous
buffer solutions at high concentration.
In using afﬁnity beads, it must be recognized that some
proteins are present in very high abundance (up to several
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some are prone to interacting generically with their hydro-
phobic or charged surfaces36. In fact, even with all the
approaches available, it is typical to identify several hundred
proteins in an afﬁnity-based chemical proteomics study37. One
strategy to reduce this problem is to introduce a control
experiment using a blank resin or an inactive compound with
similar structure to that of the target molecule38.3.2. Quantitation by stable isotope labeling
Stable isotope labeling has proven to be particularly advanta-
geous in discriminating true interactors from non-speciﬁc
binders39. As an example, Oda et al.40 used a protein isotopic
labeling strategy involving isotope-coded afﬁnity tags (ICATs)
to compare the amounts of protein present in two different cell
states. To do this, they labeled one state (the reference) with a
light isotope label and the other (the test) with a heavy isotope
label. The two samples were then mixed and analyzed by MSFigure 3 Identiﬁcation of speciﬁc protein-small molecule interactions
interactions using small molecule baits. (B) Experimental mass spectr
immobilized ligand41.
Figure 4 (A) Western-blotting analysis of MTX targets with free M
(B) Proﬁling of proteins identiﬁed in the SILAC experiment against the
‘‘light’’ peptides)28.to determine the ratio of the two isotopic distributions and
subsequently the relative amounts of protein. This quantitative
approach has proven particularly advantageous for the dis-
crimination of target proteins from non-speciﬁcally co-puriﬁed
contaminants.
More recently, Ong et al.41 described a proteome-wide
quantitative chemical proteomics method. In this work, they
combined stable isotope labeling with amino acids in cell
culture (SILAC) with MS to analyze two different cell culture
samples. The cells were grown in the presence of either heavy
or light isotope-labeled arginine/lysine and were either
untreated or pretreated with the drug of interest (Fig. 3).
The labeled proteomes were then applied to drug afﬁnity
matrices and speciﬁc interactors (which were reduced or
missing in the pretreated sample) were identiﬁed and quanti-
ﬁed. An example of the use of free ligand and SILAC for
quantitative analysis is shown in Fig. 4. By Western blotting,
the signal of the target protein can be seen to decrease
continuously with increasing free drug concentration. In
addition, most proteins showing a 1:1 ratio with and withoutwith quantitative proteomics. (A) SILAC identiﬁes speciﬁc protein
a showing speciﬁc and non-speciﬁc protein interactions with the
TX of different concentrations as the competitive binding agent.
ir log2(H/L) value (H and L are the peak areas of the ‘‘heavy’’ and
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proteins. Only proteins for which the compound competes are
considered as real target candidates worthy of further
investigation.
Another way to differentiate the binding afﬁnity of inter-
acting proteins is through the use of a coupling competitive
binding assay with stable isotope labeling. A recent report
describes the successful combination of a mixed broad
speciﬁcity kinase inhibitor matrix and free kinase inhibitor
drug elution with quantitation of drug-protein binding para-
meters using isobaric tags for relative and absolute quantita-
tion (iTRAQs)42,43. By measuring the competition with the
afﬁnity matrix, the binding curve of drugs to their targets in
cell lysates can be obtained and the binding afﬁnities of
different proteins differentiated with a high throughput MS-
based assay. Using this approach, Daub and coworkers44,45
applied SILAC to characterize changes in the kinome during
the cell cycle. To achieve this, they captured a large proportion
of the kinome by serial drug afﬁnity chromatography with
different nonspeciﬁc kinase inhibitors, allowing them to
compare the expressed kinome at two cell cycle stages. This
work represents an important milestone in the study of kinases
and kinase inhibitors since it successfully combines chemical,
phospho- and quantitative proteomics methods into a power-
ful platform that provides a cellular understanding of kinase-
and kinase inhibitor-related mechanisms.4. Application to drug target discovery
4.1. Kinase inhibitors
Protein kinases are currently one of the most investigated
classes of drug targets46 as demonstrated by the dozens of
kinase inhibitors that have entered clinical trials in recent
years. Imatinib (Gleevec), a tyrosine kinase inhibitor, is such a
drug that is now FDA-approved to treat certain types of
cancer47. As there are more than 500 known human protein
kinases and most of them engage the ATP binding pocket
which is highly conserved, selectivity is a critical issue.
Brehmer et al.48 immobilized analogs of bisindolylmalei-
mide, a potent protein kinase C (PKC) inhibitor, to proﬁle
kinase classes. They were able to identify several known and
previously unknown enzyme targets in total cell extracts of
HeLa cells. Subsequently, in vitro binding and activity assays
conﬁrmed the presence of the protein kinases, Ste20-related
kinase and cyclin-dependent kinase 2 (Cdk2), as well as the
non-protein kinases, adenosine kinase and quinone reductase
type 2, as novel targets of bisindolylmaleimide inhibitors. This
demonstrates selectivity proﬁling of closely related kinase
inhibitors within a cellular proteome. Rix et al.49 used three
BCR-ABL inhibitors, imatinib, nilotinib and dasatinib, as
afﬁnity matrices to probe the expressed kinomes/proteomes of
K562 and primary CML cells. Imatinib and nilotinib dis-
played greater target proﬁle speciﬁcity than dasatinib which
targeted a large number of Tyr and Ser/Thr kinases. Lolli
et al.50 immobilized cyclopropylpyrazole, a Cdk2 inhibitor, to
selectively enrich Cdk2 and other kinases.
Recently, ‘‘kinobeads’’ have been developed displaying the
non-selective kinase inhibitors, bosutinib, imatinib and dasa-
tinib42, and preferentially binding kinases and other purine-
binding proteins in cell lysates. Using iTRAQ quantitation,the dose-response binding proﬁles of more than 500 proteins
was determined. The combination of the mixed-afﬁnity matrix
with quantitative MS provides a versatile tool to map the direct
and indirect targets of a drug in a single set of experiments.
This approach should prove valuable at various stages of drug
discovery as well as in translational studies of drug action in
patient tissues. By mapping drug-induced changes in the
phosphorylation state of the captured proteome, it was also
possible to analyze signaling pathways downstream of the
target kinases. This technology was further applied to selective
histone deacetylase (HDAC) inhibitors with anti-cancer and
antiinﬂammatory properties43. In this study, 16 inhibitors were
clustered in terms of their effects on 1,251 proteins that
speciﬁcally interacted with the probe matrix43.
Due to the highly conserved ATP binding site, off-target
effects have been reported for several drugs. For example,
Missner et al.51 reported off-target decoding for the multi-
target protein kinase inhibitor, C1, by chemical proteomics.
Besides several kinases known to bind to the compound, the
pyridoxal kinase PDXK, known to interact with the CDK
inhibitor, (R)-roscovitine, was captured. These workers later
demonstrated that the PDXK–C1 interaction occurs at the
substrate binding site rather than at the ATP binding site.
These results greatly improve our knowledge of the off-target
proﬁle of the inhibitor. By using the ATP-competitive broad-
speciﬁcity kinase inhibitor, bosutinib, Fernbach et al.52 iden-
tiﬁed 70 individual targets in a K562 cell extract of which 19
had not been previously reported.4.2. Natural products
Natural products have shown very promising resources for
drug discovery with high structural complexity and diver-
sity53,54. However, the majority of newly discovered natural
products are only limited to biological activity with unknown
targets. It is believed that natural products are more like to
have multiple targets. Therefore, it would be essential to study
the mechanisms for the multiple component interactions.
Unlike synthesized combinatorial chemical libraries, most
natural products lack the functional groups required to attach
them to solid surfaces. It is also very difﬁcult to predict the
binding domain of small molecules that interact with
unknown proteins. Osada and coworkers55,56 developed a
non-selective universal coupling method based on a photo-
afﬁnity reaction which enabled the introduction to a solid
phase surface of a variety of small molecules such as
rapamycin, cyclosporin A, digoxigenin, digoxin, digitoxin,
and FK506. The only limitation of this approach is that it
cannot be applied to small molecules that degrade under UV
irradiation.
While chemical proteomics can identify protein targets of
small molecules, subsequent analysis of changes in the gen-
ome-wide expression pattern on exposure to the compound
can provide insight into the broader cellular context and
indicate downstream effectors of the compound-target inter-
action. Wang et al.57 immobilized levotetrahydropalmatine
(L-THP), one of the main active ingredients in the traditional
Chinese medicine, Corydalis yanhusuo, to probe the L-THP
interactome. Furthermore, they compared L-THP interaction
proteins with the proteins induced by L-THP treatment. The
combined results indicated that proteins associated with signal
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energy metabolism and ion transport play important roles in
L-THP-induced antinociception. Suzuki et al.58 prepared
afﬁnity beads bearing conophylline, a vinca alkaloid extracted
from the tropical plant Ervatamia microphylla previously
shown to induce differentiation of insulin-producing b-cells
in cultured cells and animals. Unfortunately, its mechanism of
action and molecular target remain unclear. Using conophyl-
line-linked afﬁnity beads, it was shown that conophylline
directly interacted with ARL6IP (ADP-ribosylation factor-
like 6 interacting protein) suggesting a possible mechanism of
the drug action at the molecular level. Covalently linking the
antiinﬂammatory marine natural product, petrosaspongiolide
M (PM), to solid beads led to identiﬁcation of PM interaction
proteins and evaluation of PM bioactivity both in vitro and in
living cells59.4.3. Other biological ligands
Other important bioactive molecules (enzyme inhibitors60,
metals61–63 etc.) have been examined in chemical proteomic
studies. Tian et al.64 immobilized p-aminobenzamidine (ABA),
an inhibitor of trypsin-like serine proteases, to characterize its
interacting proteins in human plasma. By proteomic analysis,
214 proteins with afﬁnity for immobilized ABA were identi-
ﬁed. Based on Gene Ontology annotation, the identiﬁed
proteases were shown to have catalytic activity and to bind
calcium and to be mainly involved in blood coagulation. In
another study, Tan et al.65 used heparin afﬁnity chromato-
graphy to analyze butyrate-treated HCT-116 colorectal cancer
cells in an attempt to better understand butyrate’s chemopre-
ventive role. These workers detected 46 differentially expressed
spots by 2-dimensional difference gel electrophoresis of which
24 were identiﬁed by MS analyses.
Dadvar et al.66 used the novel PDE5 inhibitor, PF-4540124,
as bait to probe its interactome in mouse lung tissue (Fig. 5).
Initial afﬁnity enrichment revealed the binding of hundreds of
proteins to the immobilized compound after which pre-clear-
ing and elution protocols in combination with stable-isotope
labeling were used to elimninate non-speciﬁc binding proteins.
Different isoforms of PDE5 were identiﬁed and, in addition,
a novel interactor of PF-4540124, the prenyl binding protein
PrBP, was also identiﬁed and veriﬁed by in vitro binding
assays. In another study, ampicillin was immobilized onto
agarose-based Afﬁ-Gel to target ampicillin and penicillin
binding proteins in extracts of Escherichia coli membranes.
The aim was to illuminate the mechanism of antibiotic side
effects through the identiﬁcation of non-target drug targets67.
Heck and coworkers68,69 developed an afﬁnity matrix by
immobilizing cAMP and cGMP onto agarose beads. Through
MS analysis, they identiﬁed many of the highly abundant
AMP/ADP/ATP, GMP/GDP/GTP and general DNA/RNA
binding proteins as well as cAMP/cGMP binding proteins.
Subsequently, they used solutions containing ADP, GDP,
cGMP, and/or cAMP for sequential elution and were able
to sequentially and selectively elute ADP, GDP and DNA
binding proteins. Further analysis of the cGMP/cAMP ‘‘inter-
actome’’ in rat heart ventricular tissue enabled the speciﬁc
pull-down of known cAMP/cGMP binding proteins such as
the cAMP and cGMP dependent protein kinases, PKA and
PKG, several phosphodiesterases and 6 AKAPs which interactwith PKA. In the same way, Wong et al.70 applied afﬁnity
chromatography using immobilized ATP, cAMP and cGMP
to differentially proﬁle the nucleotide-binding proteome of
active and resting platelets. The speciﬁcity of the immobilized
nucleotides was demonstrated by competitive assays and by
immunoblotting. In another report, a synthetic ATP analog,
50-p-ﬂuorosulfonylbenzoyladenosine (FSBA) was used as an
afﬁnity probe of nucleotide-binding proteins71,72. Because
adenine nucleotides are small, abundant molecules that bind
numerous proteins involved in pivotal cellular processes
and are co-factors or substrates for enzymes, regulators of
protein function, or structural binding motifs, some 185
different labeled sites were identiﬁed, several of which were
veriﬁed using three dimensional structures of the affected or
related proteins. These workers also showed that FSBA
labeled known in vivo tyrosine phosphorylation sites. Afﬁnity
matrices derivatized with synthetic phosphoinositides enabled
the capture of several multiple phosphoinositide binding
proteins in cell and tissue extracts and the identiﬁcation of
ARAP3, a novel PI3K effector regulating both Arf and Rho
GTPases73.5. Protein target of reactive intermediate metabolites
Lots of drugs will generate the reactive metabolites, which are
the short-lived intermediates and will covalently bind to
protein or DNA to cause the toxicity. The covalent binding
between drug metabolite and macromolecules was ﬁrst found
in the 1940s74. Most reactive metabolites will have low
electron densities of high actitivies and target proteins usually
contain the nucleophilic sites such as thiol and amine groups.
Now a large number of drugs were found to be able to modify
proteins leading to cell damage. Therefore, it is very important
to characterize the binding of the intermediates and the
corresponding macromolecules. To understand how the drug
induces toxicity we will not only identify the target proteins
and also need to identify the binding site of the reactive
metabolite. For example, Gardner et al.75 compared the
covalent binding of clozapine and olanzapine to human
neutrophils in vitro and in vivo. A major 58-kDa clozapine-
modiﬁed protein was detected in neutrophils of patients
treated by clozapine while only unmodiﬁed polypeptides can
be detected in neutrophils from patients taking olanzapine.
The differences in covalent binding exhibited by the two
compounds may help to explain the reason that the olanzapine
reactive metabolite did not cause toxicity toward human
neutrophils at concentrations 10 times higher than clozapine76.
Proteomics has provided an alternative approach for the study
of drug-protein interaction and the possibility of identiﬁcation of
the modiﬁcation sites. Traditionally a radiolabeled drug can be
used to treat the cells or animals and then the proteins can be
extracted and separated by two-dimensional gel electrophoresis
(2D-Gel)77. The radioactive protein spot can be cut and analyzed
by mass spectrometry78,79. Several protein targets have been
identiﬁed by this approach. For example, Isbell et al.80 used real
sample of mouse liver microsomal fractions and 14C-naphthalene
for in vitro experiment. After 2D-Gel separation and MALDI-
TOF ﬁngerprinting analysis, 18 adducted proteins were identiﬁed
to be modiﬁed by naphthalene, which needs to be further
conﬁrmed by in-vivo experiment and the modiﬁcation sites also
need to be identiﬁed by tandem mass spectrometry. Also this
Figure 5 Schematic representation of the protocols for selective enrichment of the PF-4540124 ‘‘interactome’’ and quantitative analysis
by stable isotope dimethyl-labeling66.
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Advanced mass spectrometry-based proteomics has accelerated
this process with the powerful ability of mass spectrometry for
the identiﬁcation of number of proteins without prior knowledgeof the protein sequence81. To know the toxic mechanism of
naphthalene, Zhang et al.82 extended tandem mass spectrometry
and bioinformatics analysis to identify the binding site of the
target proteins. As shown in Fig. 6, naphthalene is metabolized
Figure 6 Scheme of naphthalene quinone metabolites and MS/MS spectrum for peptide of HGTVVLTALGGILKK modiﬁed by
1,4-naphthoquinone82.
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1,4-naphthalenediol and 1,2-naphthalenediol by cytochrome
P450. The diols can be oxidized to the corresponding 1,4-
naphthoquinone and 1,2-naphthoquinone, which are good
electrophiles and can covalently bind proteins leading to the
toxic effects of naphthalene. An in-vitro experiment was
performed by incubation with hemoglobin and then the protein
was digested for mass spectrometry analysis. The MS/MS
spectrum of one peptide is shown in Fig. 6. The modiﬁcation
site can be determined by SALSA searches of the tryptic
peptide. Bateman et al.83 reported the detection of covalent
adducts to cytochrome P450 3A4 with its two known inhibitors
L-754,394 and 60,70-dihydroxybergamottin by analysis of the
intact protein adduct using top-down proteomic strategy. Theinformation may provide new source for understanding the
mechanism of covalent protein modiﬁcations in drug discovery
and development6. Prospective
As proteomic technology matures, chemical proteomics will be
more widely applied. It will provide unbiased ﬁngerprint
proﬁling of protein targets on a proteomic scale which will
substantially assist in drug optimization. More unanticipated
off-target information will also be obtained to improve the
process of drug design84. Although a number of reports have
already demonstrated the potential of afﬁnity chromatography
Lianghai Hu et al.134for drug discovery, its routine use remains to be adopted. One
issue is the high-cost of mass spectrometric analysis compared
to conventional biological assays. Another is the problem of
non-speciﬁc binding and recognition speciﬁcity. The novel
design of afﬁnity enrichment and increasing bioinformatics
analysis of the output data will be essential to the under-
standing of protein function. Last but not the least under-
standing the toxicity of the reactive metabolite is no less
important than the drug target discovery, which will greatly
decrease the chemical toxicities of a potential drug at an
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